PFM
AUTL

Privium Fund Management’s Autolus Therapeutics AUTL Stock Holding History

Privium Fund Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$581K Hold
363,430
– – 0.11% 54
2026
Q1 		$502K Buy
363,430
+37,185
+11% +$56.5K 0.1% 53
2025
Q4 		$649K Buy
326,245
+17,408
+6% +$26.7K 0.12% 47
2025
Q3 		$503K Buy
308,837
+14,695
+5% +$28.7K 0.09% 51
2025
Q2 		$674K Buy
294,142
+42,468
+17% +$70.2K 0.15% 42
2025
Q1 		$390K Buy
251,674
+20,000
+9% +$40.6K 0.1% 48
2024
Q4 		$544K Buy
231,674
+46,035
+25% +$156K 0.12% 44
2024
Q3 		$674K Buy
185,639
+25,000
+16% +$99.7K 0.17% 40
2024
Q2 		$543K Buy
160,639
+110,581
+221% +$477K 0.14% 54
2024
Q1 		$319K Buy
50,058
+15,091
+43% +$94.1K 0.09% 70
2023
Q4 		$239K Hold
34,967
– – 0.07% 68
2023
Q3 		$81.5K Sell
34,967
-32,610
-48% -$92.9K 0.02% 81
2023
Q2 		$154K Hold
67,577
– – 0.04% 77
2023
Q1 		$124K Sell
67,577
-45,951
-40% -$89.8K 0.04% 84
2022
Q4 		$205K Hold
113,528
– – 0.08% 68
2022
Q3 		$253K Buy
113,528
+15,000
+15% +$44.4K 0.09% 91
2022
Q2 		$279K Buy
98,528
+65,528
+199% +$199K 0.09% 83
2022
Q1 		$138K Buy
+33,000
New +$139K 0.03% 151

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Privium Fund Management's AUTL Position: Q2 2026 in Review

Privium Fund Management held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 363,430 shares worth $581K. The position accounts for 0.11% of the portfolio, ranked #54.

Privium Fund Management first reported a position in AUTL in Q1 2022 and has held it in 18 quarters since. The position peaked at $674K in Q3 2024. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Privium Fund Management held 363,430 shares of Autolus Therapeutics worth $581K as of Q2 2026.
  • Privium Fund Management left its Autolus Therapeutics share count unchanged in Q2 2026.
  • Autolus Therapeutics made up 0.11% of Privium Fund Management's portfolio in Q2 2026, its #54 holding.
  • Privium Fund Management first reported a position in Autolus Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Privium Fund Management's Autolus Therapeutics position peaked at $674K in Q3 2024.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Privium Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.